Tag: Bavarian
Bavarian Nordic Reports Positive Phase 3 Topline Results for Chikungunya Virus...
Chikungunya vaccine candidate met all the co-primary endpoints of the Phase 3 study and was shown to be highly immunogenic in the majority...
Bavarian Nordic Reports Omicron Data from Phase 2 Trial of its...
COPENHAGEN, Denmark, May 5, 2022 – Bavarian Nordic A/S BAVA announced today additional results from its Phase 2 clinical trial of ABNCoV2, a...
Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial...
First subject vaccinated in Phase 3 clinical trial of MVA-BN® RSV against respiratory syncytial virus (RSV) in older adultsTrial will assess efficacy of...
Bavarian Nordic Announces License and Supply Agreement with Nuance Pharma on...
Bavarian Nordic to receive up to USD 225 million in upfront and milestone payments in addition to tiered, double-digit royaltiesNuance Pharma obtains rights...